The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset

Antonio Daniele, Nicola Antonio Adolfo Quaranta, Giancarlo Logroscino, Francesco Panza, Davide Seripa, Madia Lozupone, Vincenzo Solfrizzi, Bruno P. Imbimbo, Maria Rosaria Barulli, Rosanna Tortelli, Rosa Capozzo, Paola Bisceglia, Andrea Dimitri, Roberta Stallone, Vittorio Dibello, Nicola Quaranta, Antonello Bellomo, Antonio Greco

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction: The recent failure of several clinical trials on anti-β-amyloid (Aβ) drugs in Alzheimer’s disease (AD) suggested earlier intervention in the disease course. Secondary prevention trials have been started in autosomal-dominant AD (ADAD) individuals without cognitive dysfunction and in cognitively healthy subjects at risk of developing sporadic AD (SAD). Areas covered: Herein, the authors discuss prevention trials in ADAD and SAD, with a focus on the anti-Aβ monoclonal antibodies solanezumab and gantenerumab presently in Phase III clinical development. These therapies are also being tested in the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU). Expert opinion: Anti-Aβ monoclonal antibodies are being tested in subjects at the preclinical stage of ADAD and even in symptom-free subjects at risk of developing SAD. The subsequent DIAN-TU Adaptive Prevention Trial is a 4-year study that will assess whether such biomarker effects may stop the progress of the AD process, preventing cognitive symptoms. The hope is to interfere in the disease course when it is not too late. A clinical success of these prevention trials would represent the proof of the Aβ hypothesis of AD.
Original languageEnglish
Pages (from-to)25-35
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume18
DOIs
Publication statusPublished - 2018

Keywords

  • API trials
  • Alzheimer’s disease
  • BAN2401
  • Clinical Biochemistry
  • DIAN-TU trials
  • Drug Discovery3003 Pharmaceutical Science
  • Monoclonal antibodies
  • Pharmacology
  • dementia
  • gantenerumab
  • prevention trials
  • solanezumab

Fingerprint

Dive into the research topics of 'The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset'. Together they form a unique fingerprint.

Cite this